¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cancer, leukaemia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
¿µ¹® advanced cancer ÇÑ±Û ÁøÇà¾Ï
¼³¸í   
  Á¶±â¾Ï¿¡ ´ëÇÑ ¸»·Î ¾ÏÀÇ °æ°ú°¡ ÁøÇàµÈ °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® lung cancer ÇÑ±Û Æó¾Ï
¼³¸í   
  ÇãÆÄ¿¡ »ý±â´Â ¾Ç¼ºÁ¾¾çÀÌ´Ù. °¡Àå ¿¹Èİ¡ ³ª»Û Á¾¾çÁßÀÇ Çϳª·Î½á Á¶±â¹ß°ßÀÌ ¾î·Æ°í Áõ¼¼ ¶ÇÇÑ ´Ê°Ô ³ªÅ¸³ª¼­, ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£³ª Ä¡·áÈÄ¿¡µµ ´ë°³ 8%¸¸ÀÌ 5³â »ýÁ¸ÀÌ °¡´ÉÇÑ ¾Ç¼ºÁ¾¾çÀÌ´Ù. À¯¹ßÀÎÀڷδ ´ëÇ¥ÀûÀ¸·Î ´ã¹è°¡ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, À¯ÀüÀûÀΠ¿ä¼Òµµ ¾î´À Á¤µµ ±â¿©Çϴ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
¿µ¹® cancer chemotherapy ÇÑ±Û Ç×¾ÏÈ­Çпä¹ý
¼³¸í   
  È­ÇÐÀû ¹°ÁúÀ» ÀÌ¿ëÇÏ¿© ¾ÏÀ» Ä¡·áÇϴ °ÍÀ» ¸»ÇÑ´Ù. À̶§ »ç¿ëµÇ´Â ¹°ÁúÀ» Ç×¾ÏÁ¦¶ó°í ÇÑ´Ù. ÀÌ»óÀûÀΠÇ×¾ÏÁ¦´Â Á¤»óÀûÀΠ¼¼Æ÷¿¡´Â ÀÌ»óÀÌ ¾ø°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀΠȿ°ú¸¦ ³ªÅ¸³»¾î¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀǠƯÀÌÇѠƯ¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇϴ ¾à¹°À» °³¹ßÇÏ¿©¾ß ÇÑ´Ù. ÃÖ±Ù ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº À¯ÀüÁ¤º¸¸¦ °¡Áö°í Àִ DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â(DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼­ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡¼­´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼­µµ Á¤»óÀûÀ¸·Î Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒÈ­°üÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ÀÌ·± ¼¼Æ÷°¡ ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î Ä¡¸íÀûÀΠ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼­ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒÈ­ºÒ·®ÀÌ À߿´Ù).
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • integrated cancer management
    ÅëÇÕ¾ÏÄ¡·á
  • laryngeal cancer
    ÈĵξÏ
  • liver cancer
    °£¾Ï
  • medullary cancer
    ¼ÓÁú¾Ï, ¼öÁú¾Ï
  • metastatic cancer
    ÀüÀ̾Ï
  • occult cancer
    ÀáÀç¾Ï
  • occupational cancer
    Á÷¾÷¾Ï
  • papillary cancer
    À¯µÎ¸ð¾ç¾Ï
  • primary cancer
    ¿ø¹ß¾Ï
  • prostate cancer
    Àü¸³»ù¾Ï, Àü¸³¼±¾Ï
  • prostatic cancer
    Àü¸³»ù¾Ï, Àü¸³¼±¾Ï
  • recurrent cancer
    Àç¹ß¾Ï
  • renal cancer
    ÄáÆÏ¾Ï, ½ÅÀå¾Ï
  • radiation-induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • retrograde cancer
    ÅðÇà¾Ï
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • thyroid papillary cancer
    °©»ó»ùÀ¯µÎ¾ÏÁ¾
  • undifferentiated cancer
    ¹ÌºÐÈ­¾Ï
  • cancer pain
    ¾ÏÅëÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary cancer
    ¿ø¹ß¾Ï
  • radiation-induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • recurrent cancer
    Àç¹ß¾Ï
  • retrograde cancer
    ÅðÇà¾Ï
  • small cell lung cancer
    ÀÛÀº¼¼Æ÷ÇãÆÄ¾Ï, ¼Ò¼¼Æ÷Æó¾Ï
  • soft cancer
    (¢¡medullary carcinoma) ¼ÓÁú¾ÏÁ¾, ¼öÁú¾ÏÁ¾
  • solid cancer
    °íÇü¾Ï
  • integrated cancer management
    ÅëÇÕ¾ÏÄ¡·á
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cancer control program
    ¾Ï°ü¸®°èȹ(ËâË´ËöË­Ì·), ¾Ï¿¹¹æ»ç¾÷.
  • cancer en cuirasse
    °©¿Ê¾Ï(~ äß)
  • cancer pain
    ¾Ï¼º ÅëÁõ, ¾Ï¼º µ¿Åë
  • cancer suppressor genes
    ¾Ï¾ïÁ¦À¯ÀüÀÚ(äßåäð¤ë¶îîí­)
  • cancer,grading and staging
    µî±Þ(ÔõÐä)°ú º´±â °áÁ¤(ܻѢ̽ïÒ)
  • cauliflower cancer
    ²É¾ç¹èÃß»ó¾Ï, ¹èÃ߸ð¾ç¾Ï
  • cauliflower cancer
    Á¼ÀÍ
  • cervical cancer
    ÀڱðæºÎ¾Ï
  • conjugal cancer
    ºÎºÎ¾Ï(ÜýÜþäß).
  • corset cancer
    ÄÚ¸£¼Â¾Ï(¡­äß).
  • corset cancer
    ÄÚ¸£¼Â ¾Ï(¡­äß).
  • cuirass cancer
    ÈäºÎ°æÈ­ÀüÀ̼º À¯¾Ï(ýØÝ»Ìãûùï®ì¹àõêáäß), Èä°©¾Ï.
  • cuirass cancer
    ÈäºÎ(ÀüÀ̼º)ÇǺξÏ(ÈäºÎÀüÀ̼ºÇǺξÏ).
  • cutaneous cancer
    ÇǺξÏ(ù«Ý± )
  • duct cancer
    °ü¾Ï(°ü¾Ï).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AJCC American Joint Committee on Cancer
CA-125 Cancer Antigen-125
Ca   1) Carcinoma
  2) Cancer; ¾Ï
  3) Calcium
EGC Early Gastric Cancer
TAE Trans-Arterial(-Catheter) Embolization
  Angiography¿Í µ¿½Ã¿¡ Gel Form°ú CTx AgentÀÇ Mixed m...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AML Acute Myeloid Leukaemia
APL Acute Promyelocytic Leukaemia
AMoL Acute monocytic leukaemia
ATL Adult T Cell Leukaemia
ATL Adult T cell leukaemia-lymphoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mouth cancer
    ±¸°­ ¾Ï
  • occupational cancer
    Á÷¾÷ ¾Ï
  • oral cancer
    ±¸°­ ¾Ï
    Àüü ¾Ï ¹ß»ý ºóµµ¿¡¼­ ¾à 3¡­4%¸¦ Â÷ÁöÇÏ´Â ±¸°­ ¾ÏÀº Çô, »´, Ä¡ÁÖÁ¶Á÷, ¶Ç´Â ±¸ÀεÎÀÇ ¾î´À ºÎÀ§¿¡µµ ħ¹üÇÒ ¼ö ÀÖ´Ù. ÀÌ´Â ±¸°­ ³»ÀÇ ¹ß»ý À§Ä¡¿¡ µû¶ó ´Þ¶óÁö±â´Â ÇÏÁö¸¸ ´ë°³ ¿©ÀÚº¸´Ù´Â ³²ÀÚ¿¡°Ô¼­ ¾à 2~6¹è ¸¹ÀÌ ¹ß»ýÇÏ¸ç ¿ì¸® ³ª¶ó¿¡¼­´Â 1³â¿¡ ¾à õ ¸í ³»Áö ÀÌ Ãµ¸íÀÇ »õ·Î¿î ±¸°­ ¾Ï ȯÀÚ°¡ ¹ß»ýÇϱ⠶§¹®¿¡ ±¸°­ ¾ÏÀ¸·Î Åõº´ ÁßÀΠȯÀÚ¸¸µµ ¼ö ¸¸ ¸í¿¡ À̸¥´Ù. 1996³â¿¡ ½ÃÇàÇÑ ÈÄÇ⼺ ¿¬±¸¿¡ ÀÇÇϸé Àüü ±¸°­ ¾Ï ȯÀÚÀÇ Æò±Õ 5³â »ýÁ¸À²Àº ¾à 46%·Î ¹Ý ÀÌ»óÀÇ È¯ÀÚ°¡ 5³â À̳»¿¡ »ç¸ÁÇÏ´Â °ÍÀ¸·Î Á¶»çµÈ¹Ù ÀÖ´Ù. ±¸°­ ¾ÏÀÇ À¯º´·üÀº ¿¬·É Áõ°¡¿Í °ü·ÃÀÌ ÀÖ´Ù. 40¼¼ ÀÌÈÄ¿¡ ¹ß»ý·üÀÌ ±ØÀûÀ¸·Î Áõ°¡Çϱ⠽ÃÀÛÇÏ¿© 60¼¼ÀÇ ¿¬·É¿¡¼­ ÀÏÁ¤ÇÑ À¯Áö °î¼±À» Çü¼ºÇÑ´Ù. ¾î¶² ¿ä¼Ò°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Å« ¿µÇâÀ» ³¢Ä¡´Â°¡¿¡ ´ëÇÑ ¹®Çå ¿¬±¸¿¡¼­ ´ã¹è¿Í ¼úÀÌ ¸ðµç ±¸°­ ¾ÏÀÇ 75%¸¦ ¾ß±âÇØ ÀÌ Áúȯ¿¡ °¡Àå Å« ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. Èí¿¬°ú °úÀ½ÀÌ °¢°¢ ±¸°­ ¾ÏÀÇ À§Ç輺À» Áõ°¡½ÃŰ´Â ¹Ý¸é, ±×µéÀÇ »óÇÕÈ¿°ú´Â ±× ¸î ¹èÀÎ °ÍÀ¸·Î ³ªÅ¸³ª¼­ °ñÃÊ¿¡ ¾ËÄÝ Áßµ¶À̶ó¸é Á¤»óÀÎÀÇ ¾à 30¹è ÀÌ»ó ÀÌȯÀ²ÀÌ ³ô¾ÆÁø´Ù. ±¸°­ ¾ÏÀÇ ÈçÇÑ Àü±¸ Áõ»óÀ¸·Î ¾Ë·ÁÁø ¹é¹ÝÁõÀº ±¸°­ Á¡¸·¿¡ Èò ¹éŸ¦ º¸ÀÌ´Â º´º¯À¸·Î ÀÌ ÁúȯÀÌ ¾ÏÁ¾À¸·Î ÁøÇàµÉ È®·üÀº 0.1%~36%ÀÇ ¸Å¿ì ´Ù¾çÇÑ ÆíÂ÷·Î º¸°íµÇ°í ÀÖÀ¸³ª ÀϹÝÀûÀ¸·Î´Â 10Áõ·Ê Áß 1Áõ·Ê°¡ ÀÌÇàµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Àß ÀûÇÕµÇÁö ¾Ê´Â Ʋ´Ï³ª ¿À·¡ »ç¿ëÇÏ¿© ¸¶¸ðµÇ°í ³¯Ä«·Î¿öÁø ±Ý°ü µî¿¡ ÀÇÇÏ¿© Çù Á¡¸·À̳ª Çô, ¹«Ä¡¾Ç Ä¡Á¶Á¤ Á¡¸· µî¿¡ ¹ß»ýµÇ´Â ±Ë¾ç¼º º´º¯Àº Á¾±¹¿¡´Â ±¸°­ ¾ÏÀ¸·Î ÀüÀ̵DZ⠽¬¿î °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾î ÁÖ±âÀûÀÎ Ä¡°ú °ËÁøÀÌ ÇÊ¿äÇÏ´Ù. ±¸°­ ¾ÏÀÇ À§Çè ¿ä¼Ò Áß¿¡´Â À¯ÀüÀû ¿ä¼Òµµ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ƯÁ¤ Áý´Ü Áß¿¡´Â ¾ÏÀ» °¡Áö°í ÀÖ´Â °¡Á·ÀÌ ÀÖÀ¸¸é ±¸°­ ¾ÏÀÇ ¹ß»ý À§Ç輺ÀÌ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Èí¿¬°ú À½ÁÖ°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Áß¿äÇÑ ¿äÀÎÀ̱⠶§¹®¿¡ Áß´ÜÇϰųª ÃÖ¼ÒÇÑ ÁÙÀÌ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ´Ù. °Ç°­ÇÑ ½Ä»ýȰÀº ±¸°­ ¾ÏÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù. ½Å¼±ÇÑ °úÀÏÀ̳ª ³ì»ö ä¼Ò´Â ±¸°­ ¾Ï ¹ß»ý·üÀ» °¨¼Ò½Ãų ¼ö ÀÖ°í, ÀÌ´Â ºñŸ¹Î A, C, E°¡ ÇÔÀ¯µÈ À½½ÄÀÌ ¿¹¹æ È¿°ú¸¦ °®´Â´Ù´Â »ç½ÇÀ» µÞ¹ÞħÇÑ´Ù. ±¸°­ Á¡¸·À» µ¥ÀÏ Á¤µµÀÇ ¶ß°Å¿î À½½ÄÀ̳ª ÀڱؼºÀÇ À½½ÄÀº ÇÇÇϵµ·Ï ÇÏ´Â °ÍÀÌ ÁÁ´Ù. HPVÀÇ ¹ßÇöÀ̳ª P53 À¯Àü ÀÎÀÚÀÇ º¯À§¿Í °°Àº ƯÁ¤ À¯ÀüÇÐÀû ¶Ç´Â Ãʱ⠼¼Æ÷ º¯È­°¡ ±¸°­ ¾Ï°ú °ü·ÃÀÌ ÀÖ´Ù´Â ¹ß°ßÀº ÃÖ±Ù ÁÖ¸ñ¹Þ°í ÀÖ´Â ¿¬±¸ÀÌ´Ù. °¡±î¿î ¹Ì·¡¿¡´Â ±¸°­ ¾ÏÀÇ À§Ç輺ÀÌ ³ôÀº ȯÀÚÀÇ ±¸°­ Á¡¸·À» ÁÖ±âÀûÀ¸·Î °Ë»çÇϰųª Ãʱ⠼¼Æ÷ º¯È­¸¦ º¸À̴ ȯÀÚ¸¦ ÀÎÁöÇÏ´Â °ÍÀÌ °¡´ÉÇÒ °ÍÀÌ´Ù. ±¸°­ ¾ÏÀÇ Á¶±â ¹ß°ß°ú Ä¡·á¸¦ À§ÇÑ À¯¿ëÇÑ ±â¼úÀÇ °³¹ßÀº ÀÌ ºÐ¾ß¿¡¼­ ±â´ëµÈ´Ù. ±¸°­ ¾ÏÀº ¹ß»ý Ãʱ⿡´Â º°´Ù¸¥ Áõ»óÀ» º¸ÀÌÁö ¾Ê°í ¼­¼­È÷ ÁøÇàµÇ±â ¶§¹®¿¡ Á¶±â ¹ß°ßÀÌ ¹«Ã´ ¾î·Æ´Ù. ±¸°­ ¾Ç¾È¸é ¿µ¿ªÀÇ ¾ÏÀÇ Á¶±â ¹ß°ßÀº ¿©·¯ °¡Áö ÀÓ»óÀûÀÎ ¹ß°ßÀÌ ±âÃʰ¡ µÇ´Âµ¥ Ãʱ⿡´Â ´ë°³ ºÓÀº È«¹ÝÁõÀ» º¸À̸ç Á¡¸·ÀÌ °ÅÄ¥¾îÁö°í ¾à°£ À¶±âµÇ³ª À̶§´Â ¿°Áõ¼º º´¼Ò¿Í ºñ½ÁÇÏ¿© °¨º°ÀÌ °ï¶õÇÏ´Ù. ÀÌÈÄ ÁøÇàµÇ¾î ÀԾȿ¡ Èò ¸·ÀÌ »ý±â°Å³ª ÀÔ¾ÈÀÌ Çæ¾î ±Ë¾çÀÌ »ý±â°í º¸¸§ ÀÌ»ó ³´Áö ¾Ê°í Áö¼ÓµÇ´Â °æ¿ìµµ ÀÖ´Ù. ÀԾȿ¡ ¸¸¼ºÀûÀ¸·Î ¹é»ö º´¼Ò°¡ ÀÖ´Â °æ¿ì, ¸ñ¿¡ ¸Û¿ïÀÌ »ý±â°í ¾ø¾îÁöÁö ¾Ê´Â °æ¿ì ±¸°­ ¾ÏÀÌ ÀǽɵǹǷΠÁ» ´õ ¼¼¹ÐÇÑ Áø´ÜÀ» ¹Þ¾Æº¸´Â °ÍÀÌ ±ÇÀåµÇ¸ç Á¶±â Áø´Ü ½Ã »ýÁ¸À²Àº ÇöÀúÇÏ°Ô ³ô¾ÆÁö°Ô µÈ´Ù. ±¸°­ ¾Ï Ä¡·á ¹æ¹ýÀº ´ëÇ¥ÀûÀ¸·Î ¿Ü°úÀû ¼ö¼ú, ¹æ»ç¼± ¿ä¹ý, Ç×¾Ï ¿ä¹ýÀ¸·Î ÀÌ·ç¾îÁö¸ç ´Üµ¶À¸·Î ¶Ç´Â º¹ÇÕÀûÀ¸·Î ½ÃÇàµÈ´Ù. ÃÖ±Ù¿¡ ¸é¿ª ¿ä¹ý, ±¤ ¿¡³ÊÁö ¿ä¹ý µîÀÌ °³¹ßµÇ°í ÀÖÀ¸³ª ¾ÆÁ÷ ÀÓ»óÀûÀ¸·Î Ȱ¹ßÈ÷ ÀÌ¿ëµÇ°í ÀÖÁö´Â ¸øÇÏ´Ù. ±¸°­ ¾Ç¾È¸é ºÎÀ§ÀÇ Á¾¾çÀÇ ÀýÁ¦ ½Ã¿¡´Â Åë»ó ¾Ç¾È¸é ºÎÀ§ÀÇ °á¼ÕÀ¸·Î ±â´É Àå¾Ö¿Í ¾È¸ð ÃßÇü µîÀÇ ½É¹ÌÀûÀÎ ¼Õ»ó°ú ÀÌ¿¡ µû¸¥ Á¤½Å ½É¸®Àû ¹®Á¦Á¡À» ¾ß±âÇÒ ¼ö ÀÖ´Ù. ±¸°­ ¾Ï ÀýÁ¦¼ú ÈÄ ¾Ç°ñ ¹× ¿¬Á¶Á÷ °á¼ÕÀÌ ÀÖ´Â °æ¿ì¿¡ ¾Ç°ñ Àç°ÇÀ» ´Ü¼øÈ÷ º¹¿øÀ̶ó´Â °³³äÀ» ¶°³ª ½É¹ÌÀûÀ̰í ÀúÀÛ ±â´ÉÀÇ È¸º¹À̶ó´Â Â÷¿ø¿¡¼­ Àç°ÇÇÏ¿© »çȸÀûÀ¸·Î º¹±ÍÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.
  • pancreas cancer
    ÃéÀå ¾Ï
    ÃéÀå¿¡ »ý±â´Â ¾Ï. ÃéÀå
  • pancreatic cancer
    ÃéÀå ¾Ï
  • radiation induced cancer
    ¹æ»ç¼± À¯¹ß ¾Ï, X¼± ¾Ï
  • renal cancer
    ½Å ¾Ï
  • retrograde cancer
    ÅðÇ༺ ¾Ï
  • scar cancer
    ¹ÝÈç ¾Ï
    ¹ÝÈçÀÌ ¾ÏÀÇ ¿øÀÎ, Æó ¾Ï¿¡ ¸¹´Ù.
  • smoker s cancer
    Èí¿¬ÀÚ ¾Ï
  • tongue cancer
    ¼³ ¾Ï
    Çô¿¡ »ý±â´Â ¾Ï.
  • vaginal cancer
    Áú ¾Ï
  • water cancer
    ¼ö¾Ï. ±«»ç¼º ±¸³»¿°
    µ¿ÀǾî=gangrenous stomatitis.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
avian leukaemia-sarcoma complex A term applied to a group of transmissible virus-induced diseases of chickens causing sarcoma, myeloblastosis, erythroblastosis, leukosis, osteopetrosis, and lymphomatosis. These agents are closely related viruses (avian leukosis-sarcoma virus) causing prolferation of immature erythroid, myeloid, or lymphoid cells, a division of the RNA tumour viruses (subfamily Oncovirinae) causing the avian leukosis-sarcoma complex of diseases; the viruses are subgrouped according to antigenic characteristics and growth in defined types of tissue culture cells.
Synonym: avian erythroblastosis virus, avian leukosis-sarcoma virus, avian lymphomatosis virus, avian myeloblastosis virus, avian sarcoma virus, fowl erythroblastosis virus, fowl lymphomatosis virus, fowl myeloblastosis virus.
(05 Mar 2000)
avian leukaemia virus <virology> Group of C type RNA tumour viruses (Oncovirinae) that cause various leukaemias and other tumours in birds.
The acute leukaemia viruses, that are replication defective and require helper viruses, include avian erythroblastosis (AEV), myeloblastosis (AMV) and myelo cytomatosis viruses.
AEV carries two transforming genes, v erbA and v erbB, the cellular homologue of the latter is the structural gene for the epidermal growth factor receptor. AMV carries v myb and causes a myeloid leukaemia, avian myelocytomatosis virus carries v myc.
The avian lymphatic leukaemia viruses (ALV) are also Retroviridae but are replication competent and induce neoplasia only after several months, they often occur in conjunction with replication defective leukaemia viruses.
(02 Jan 1998)
basophilic leukaemia A form of granulocytic leukaemia in which there are unusually great numbers of basophilic granulocytes in the tissues and circulating blood; in some instances, the immature and mature basophilic forms may represent from 40 to 80% of the total numbers of white blood cells.
Synonym: mast cell leukaemia.
(05 Mar 2000)
B-cell leukaemia A test which detects the presence of antigens on the surface of B lymphocytes. These antigens can indicate the presence of leukaemia. most often this is used to detect and differentiate chronic lymphocytic leukaemia from acute lymphocytic leukaemia.
Origin: Gr. Haima = blood
(27 Sep 1997)
bovine leukaemia A lymphoid neoplastic disease in cattle caused by the bovine leukaemia virus. Enzootic bovine leukosis may take the form of lymphosarcoma, malignant lymphoma, or leukaemia but the presence of malignant cells in the blood is not a consistent finding.
(12 Dec 1998)
bovine leukaemia virus A type C retrovirus in the subfamily Retrovirinae, commonly infecting cattle, especially dairy cows; in a small proportion of infected cattle, it will cause enzootic bovine leukosis.
Synonym: bovine leukosis virus.
(05 Mar 2000)
radiation leukaemia virus A murine leukaemia virus isolated from radiation-induced lymphomas in c57bl mice. It is leukemogenic, thymotrophic, can be transmitted vertically, and replicates only in vivo.
(12 Dec 1998)
Maloney leukaemia virus A retrovirus associated with leukaemia in rodents.
(05 Mar 2000)
Rauscher leukaemia virus An RNA retrovirus associated with leukaemia in rodents; similar to Friend virus.
Synonym: Rauscher's virus.
(05 Mar 2000)
mast cell leukaemia A form of granulocytic leukaemia in which there are unusually great numbers of basophilic granulocytes in the tissues and circulating blood; in some instances, the immature and mature basophilic forms may represent from 40 to 80% of the total numbers of white blood cells.
Synonym: mast cell leukaemia.
(05 Mar 2000)
mature cell leukaemia Chronic granulocytic leukaemia.
(05 Mar 2000)
megakaryocytic leukaemia An unusual form of myelopoietic disease that is characterised by a seemingly uncontrolled proliferation of megakaryocytes in the bone marrow, and sometimes by the presence of a considerable number of megakaryocytes in the circulating blood. When bone marrow is examined at various intervals in some instances of chronic myelocytic leukaemia, the proliferation of megakaryocytes is more prominent than that of the granulocytes; at such times, the circulating blood may contain megakaryocytes or fragments of megakaryocytic nuclei and cytoplasm, or both, amounting to as much as 5 or 6% of the total number of leukocytes.
(05 Mar 2000)
meningeal leukaemia Infiltration of the meninges by leukaemic cells, a common occurrence in relapse following systemic administration of chemotherapeutic agents to leukaemia patients.
(05 Mar 2000)
granulocytic leukaemia <haematology, tumour> A form of leukaemia characterised by an uncontrolled proliferation of myelopoietic cells in the bone marrow and in extramedullary sites, and the presence of large numbers of immature and mature granulocytic forms in various tissues (and organs) and in the circulating blood.
The total count may range from 1000 (aleukaemic variety) to several hundred thousand per cu mm. The predominant cell is usually of the neutrophilic series, but, in a few instances, eosinophilic or basophilic granulocytes, or even megakaryocytes, may represent the chief form; early in granulocytic leukaemia, the circulating blood may contain excessive numbers of all of the granulocytic forms.
Synonym: leukaemic myelosis, myelocytic leukaemia, myelogenic leukaemia, myelogenous leukaemia, myeloid leukaemia.
(05 Mar 2000)
Rieder cell leukaemia A special form of acute granulocytic leukaemia in which the affected tissues and the circulating blood contain relatively large numbers of atypical myeloblasts (i.e., Rieder cells) that have the usual, faintly granular, immature type of cytoplasm, and a bizarre, comparatively mature nucleus with several wide and deep indentations (suggestive of lobulation).
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á